{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:21:14Z","timestamp":1788621674122,"version":"build-2803163510"},"reference-count":19,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>&lt;p&gt;Introduction: Ruxolitinib is approved for treatment of myelofibrosis. We evaluated ruxolitinib in patients with anemia (hemoglobin &lt;10 g\/dL) or thrombocytopenia (platelet count \u2264100 \u00d7 109\/L) at diagnosis. Methods: This was a retrospective, secondary analysis of a Cardinal Health Oncology Provider Extended Network medical chart review of adults with myelofibrosis diagnosed between 2012 and 2016 who received first-line ruxolitinib. Results: 176 patients received first-line ruxolitinib and were included in this analysis. At diagnosis, 120 patients had hemoglobin concentrations &lt;10 g\/dL and 59 had a platelet count \u2264100 \u00d7 109\/L. Most patients (95%) with thrombocytopenia also had anemia. Median time of observation after diagnosis was 21.4 months. Among patients with anemia or thrombocytopenia, ruxolitinib dose at end of study was \u226510 mg twice daily (bid) in 88.3% and 83.1%, respectively. Ruxolitinib treatment was ongoing in 76.1% of patients overall and was rarely discontinued for anemia or thrombocytopenia (n = 2 total, 1.1%). Per the treating physician, 79.7% of patients had improved symptoms and 62.7% improved spleen size. Conclusion: Most patients with myelofibrosis and anemia or thrombocytopenia at diagnosis tolerated and maintained a ruxolitinib dose \u226510 mg bid for nearly 2 years, resulting in clinical benefit. This real-world evidence supports observations from prospective clinical trials of ruxolitinib in myelofibrosis. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000541549","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:00:44Z","timestamp":1729512044000},"page":"408-418","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis"],"prefix":"10.1159","volume":"148","author":[{"given":"Jingbo","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cordaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000279"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13005"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000340"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204602"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.016"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01261-x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16462"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1358"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04055-w"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34722"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16729"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/doi\/10.1159\/000541549\/4300780\/000541549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000541549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:02:49Z","timestamp":1758297769000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000541549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1159\/000541549","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}